Xia X - Search Results

1

Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models.

Hu J, Lazar AJ, Ingram D, Wang WL, Zhang W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, Gorlick R, Li S. Hu J, et al. Among authors: xia x. J Immunother Cancer. 2024 Jan 9;12(1):e006991. doi: 10.1136/jitc-2023-006991. J Immunother Cancer. 2024. PMID: 38199607 Free PMC article.

2

Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.

Zhao Q, Hu J, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S. Zhao Q, et al. Among authors: xia x. J Immunother Cancer. 2019 Jun 17;7(1):154. doi: 10.1186/s40425-019-0631-z. J Immunother Cancer. 2019. PMID: 31208461 Free PMC article.

3

Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors.

Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, Dao L, Xia X, Natalie Wall F, Zhang Z, Mahadeo K, Gorlick R, Kopetz S, Dotti G, Li S. Hu J, et al. Among authors: xia x. J Immunother Cancer. 2022 Jan;10(1):e003633. doi: 10.1136/jitc-2021-003633. J Immunother Cancer. 2022. PMID: 35027427 Free PMC article.

4

Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma.

Yang Q, Hu J, Jia Z, Wang Q, Wang J, Dao LH, Zhang W, Zhang S, Xia X, Gorlick R, Li S. Yang Q, et al. Among authors: xia x. Clin Cancer Res. 2022 Sep 1;28(17):3862-3873. doi: 10.1158/1078-0432.CCR-22-0721. Clin Cancer Res. 2022. PMID: 35727602 Free PMC article.

5

CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.

Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. Hu J, et al. Among authors: xia x. Mol Cancer. 2014 Feb 24;13:34. doi: 10.1186/1476-4598-13-34. Mol Cancer. 2014. PMID: 24565056 Free PMC article.

6

Potential Function of Exogenous Vimentin on the Activation of Wnt Signaling Pathway in Cancer Cells.

Satelli A, Hu J, Xia X, Li S. Satelli A, et al. Among authors: xia x. J Cancer. 2016 Aug 12;7(13):1824-1832. doi: 10.7150/jca.15622. eCollection 2016. J Cancer. 2016. PMID: 27698922 Free PMC article.

7

Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8⁺ T Cells and Histone Acetyltransferases.

Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S. Hu J, et al. Among authors: xia x. Cancer Immunol Res. 2017 Apr;5(4):300-311. doi: 10.1158/2326-6066.CIR-16-0234. Epub 2017 Feb 21. Cancer Immunol Res. 2017. PMID: 28223282 Free PMC article.

8

T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Hu J, Sun C, Bernatchez C, Xia X, Hwu P, Dotti G, Li S. Hu J, et al. Among authors: xia x. Clin Cancer Res. 2018 Jun 15;24(12):2920-2934. doi: 10.1158/1078-0432.CCR-17-1365. Epub 2018 Feb 1. Clin Cancer Res. 2018. PMID: 29391351 Free PMC article.

9

Induction of NKG2D ligand expression on tumor cells by CD8⁺ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor.

Hu J, Xia X, Gorlick R, Li S. Hu J, et al. Among authors: xia x. Oncogene. 2019 Dec;38(49):7433-7446. doi: 10.1038/s41388-019-0960-x. Epub 2019 Aug 19. Oncogene. 2019. PMID: 31427736 Free PMC article.

10

Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance.

Hu J, Xia X, Zhao Q, Li S. Hu J, et al. Among authors: xia x. Cancer Lett. 2021 Apr 1;502:143-153. doi: 10.1016/j.canlet.2020.12.002. Epub 2020 Dec 3. Cancer Lett. 2021. PMID: 33279621 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8,422 results

Search Page